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Introduction. Photodynamic therapy is a two-step procedure, involving the use of
photosensitizing agents followed by selective illumination of the target lesion with visible light.
It produces highly reactive oxygen species and subsequent cellular damage.
Objective. This study was designed to determine whether Leishmania chagasi and L.
panamensis promastigotes were sensitive to photodynamic therapy in vitro.
Material and methods. Leishmania promastigotes were treated with aluminium phthalocyanine
chloride and zinc phthalocyanine photosensitizers before illumination with visible light at 670
nm. The parasite photoactivity was calculated by sigmoidal regression analysis.
Results. Leishmania chagasi promastigotes were highly photosensitive to aluminium
phthalocyanine chloride treatment with effective inhibitory dose50 (ED50) concentration values of
0.0033, 0.0083 and 0.0093 µM upon exposure to 10.0, 5.0, and 2.5 J/cm2 light intensities
respectively. By contrast, the activity of aluminium phthalocyanine chloride on L. panamensis
was significantly lower (P<0.01) with ED50 values of 0.17, 0.25, 0.34 µM at the same light
intensities. Zinc phthalocyanine activity was significantly (P<0.01) less active than aluminium
phthalocyanine chloride on both strains of these two species and no differences in zinc
phthalocyanine activity were found between them. A dose-response phototoxic effect with both
phthalocyanines was observed. Parasite inhibition was not observed after aluminium
phthalocyanine chloride or zinc phthalocyanine treatment in the dark. The reference drugs
hexadecylphosphocholine and amphotericin B were not photoactive.
Conclusion. Treatment of Leishmania promastigotes with aluminium phthalocyanine chloride
and zinc phthalocyanine followed by illumination with visible light at 670 nm inhibited in vitro
growth of promastigotes of L. chagasi and L. panamensis. Photodynamic therapy against
Leishmania could be a promising strategy for leishmaniasis treatment.
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Actividad fotodinámica de ftalocianina de aluminio (iii) y zinc (ii) en promastigotes de
Leishmania
Introducción. La terapia fotodinámica es un procedimiento en dos pasos que usa un agente
fotosensibilizador y luz visible produciendo radicales de oxígeno altamente reactivos originando
daño celular.
Objetivo. En este estudio se determinó la fotosusceptibilidad de promastigotes de dos cepas
de las especies Leishmania chagasi y L. panamensis a la terapia fotodinámica in vitro.
Materiales y métodos. Promastigotes de Leishmania fueron tratados con ftalocianina de
aluminio clorada o ftalocianina de zinc antes de la irradiación con luz visible a 670 nm. La
fotoactividad fue calculada por regresión sigmoidea.
Resultados. Los promastigotes de L. chagasi fueron altamente fotosensibles al tratamiento
con ftalocianina de aluminio clorada con valores de concentraciones inhibitorias50 de 0,0033,
0,0083 y 0,0093 µM utilizando una intensidad de luz de 10,0, 5,0 y 2,5 J/cm2 respectivamente.
La actividad de la ftalocianina de aluminio clorada en promastigotes de la cepa de L.
panamensis fue significativamente menor (P<0,01) que en la cepa  L. chagasi con valores de
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ED50 de 0,17, 0,25, 0,34 µM respectivamente. El tratamiento con ftalocianina de zinc fue
significativamente menos fotoactivo (P<0,01) en ambas especies sin diferencia significativa
en la actividad entre ellas. El efecto fototóxico inducido por las ftalocianinas fue dependiente
de la dosis utilizada. No se presentó fototoxicidad en condiciones de oscuridad. Los
medicamentos de referencia hexadecilfosfocolina y anfotericina B no fueron fotoactivos.
Conclusión. El tratamiento de promastigotes de Leishmania con ftalocianinas seguido de la
irradiación con luz visible a 670 nm inhibió el crecimiento in vitro de promastigotes de L.
chagasi y L. panamensis. La terapia fotodinámica contra la Leishmania podría ser una estrategia
promisoria en el tratamiento de leishmaniasis.
Palabras clave: Leishmania, fotoquimioterapia, quimioterapia, in vitro.
The leishmaniases are a group of diseases caused
by trypanosomatid protozoa of the genus
Leishmania transmitted to humans by the bite of
an infected sandfly. Leishmaniasis occurs in
approximately 88 countries in the New and Old
World where 350 million individuals are exposed,
12 million are infected and 1.5 to 2 million new
cases of cutaneous leishmaniasis and half a million
of visceral leishmaniasis are reported annually (1).
Since the 1940s, pentavalent antimonial (SbV)
drugs have been the treatment of choice for all
forms of human leishmaniasis. Other drugs such
as amphotericin B, pentamidine isothionate and
aminosidine (paromomycin) constitute the tradi-
tional alternatives to SbV for leishmaniasis treat-
ment (2). However, currently available drugs re-
quire parenteral administration, many vary in effi-
cacy and are toxic and expensive. Moreover, re-
sistance to the most widely used antileishmanial
drugs has been reported (3). The process of drug
discovery in leishmaniasis is difficult due to the
biological characteristics of the parasite and to
the lack of economical incentives for pharma-
ceutical companies to invest in the development
of new treatments. Fortunately, the current
situation is more promising than it has been for
several years. The duration of treatment has been
reduced, oral instead of parenteral administration
is now available, and new drugs, formulations or
dosage regimens of old drugs with less toxicity
are also on clinical trials (4-6).
Photodynamic therapy is a two-step procedure that
uses a combination of photosensitizer agents and
visible light in the presence of molecular oxygen
to obtain a therapeutic effect (7). It has been used
as an alternative procedure for detection and treat-
ment of cancer and other skin illnesses like pso-
riasis and vitiligo (8). Photodynamic therapy has
been used to eliminate in vitro microorganisms
such as bacteria, yeasts, viruses and parasites
and successfully in disinfection of blood products.
In addition, it has become a potential low cost
treatment for local skin infections (9-12).
Photosensitizer agents such as phenothiazine
dyes, porphyrins and phthalocyanines contain
macrocyclic structures with accessible sites for
triplet excited states under visible light radiation.
They have the ability to accumulate in unhealthy
tissues and cells exhibiting little or no toxicity;
however, after light illumination in the presence of
molecular oxygen, they are excited and a lethal
effect on infected tissues is induced.
Photooxidation reactions are produced by radical
intermediates subsequently scavenged by oxygen
or by the generation of the highly cytotoxic
monovalent oxygen (O.-) after energy transfer from
the photoexcited sensitizer (8,13,14).
Phthalocyanines (figure 1) are a new generation
of photosensitizer agents for photodynamic
therapy (15-17). These compounds are good can-
didates for photodynamic therapy because they
are efficiently incorporated into target cells, are
non-toxic for healthy cells, exhibit high yield of
triplet states generation, and induce an optimal
light tissue penetration by their high absorbance
coefficients at 650-680 nm (18,19). The
photophysical properties of phthalocyanines are
strongly dependent on the central metal ion. For
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application in photodynamic therapy, Zn (II) and
Al (III) complexes exhibit the most favourable prop-
erties. Unfortunately most phthalocyanines are in-
soluble in water or in biologically compatible
solvents. However, water-soluble phthalocyanines
derivatives can be readily synthesised through
substitution of the ring with moieties such as
sulphonic acid, carboxylic acid and amino groups
(15).
While the use of the photodynamic therapy in can-
cer treatment is well accepted, its use against
microorganisms is a relatively new area of research
and, at least in the case of Leishmania, it is in
exploratory stages (20,21). Early in vitro investi-
gations showed that some electron carriers and
porphyrins in combination with menadione induced
a selective destruction of intracellular amastigotes
(22-24). Further experiments demonstrated that
transgenic Leishmania parasites, expressing the
second and third enzymes involved in the synthe-
sis of heme metabolic pathway such as
aminolevulinate dehydratase and porphobilinogen
deaminase respectively, become highly suscep-
tible to ultraviolet l ight exposition after
aminolevulinic acid treatment (20). Recently, the
efficacy of photodynamic therapy treatment was
demonstrated on human skin lesions caused pos-
sibly by Leishmania donovani parasites, using
aminolevulinic acid as photosensitizer (21).
Figure 1. General structure of phthalocyanines where M is
the central metal ion (Al, Zn, Co, etc.) and R represent the
possible ring substituents (15).
In order to investigate for new chemotherapeutic
strategies on leishmaniasis, the aim of this study
was to determine the in vitro photodynamic activ-
ity of aluminium chloride and zinc phthalocyanines
in promastigotes of Leishmania panamensis and
L. chagasi parasites.
Materials and methods
Phthalocyanines and reference drugs
Aluminium phthalocyanine chloride (AlPc) and zinc
phthalocyanine (ZnPc) were purchased from
Sigma-Aldrich (St. Louis, USA). Stock solutions
were prepared in dimethylformamide (Fluka).
Working solutions were made in culture medium
immediately before the assays. Dimethyl-
formamide was not toxic for the parasites at the
dilution used. Hexadecylphosphocholine, kindly
provided by Professor Simon Croft (London School
of Hygiene and Tropical Medicine, UK), and am-
photericin B purchased from Sigma were used as
reference drugs.
Parasites
L. panamensis (MHOM/PA/71/LS94) and L.
chagasi parasites (MHOM/BR/74/PP75) were
kindly donated by the Centro Internacional de
Entrenamiento e Investigaciones Médicas
(CIDEIM), Cali, Colombia. Parasite promastigotes
were cultured at 28°C in minimal essential medium
(MEM, Gibco, USA) supplemented with 10% of
heat inactivated foetal calf serum (hiFCS, Gibco).
Phototoxic assays on
Leishmania promastigotes
Parasites were harvested in the late exponential
growth phase, diluted to 1 x 106 parasites/ml and
incubated with control drugs, AlPc or ZnPc using
a three-fold dilution series (from 0 µM to 15 µM),
in 96 microwell plates (Becton Dickinson, New
Jersey, USA) for 24 hours at 28°C. The parasites
were illuminated using light intensities of 10.0 J/
cm2, 5.0 J/cm2 and 2.5 J/cm2 at 670 nm with a
non-ionic red laser light system (BFW, Edmund
Industrial Optics). Control cells were not
illuminated. Twenty-four hours after illumination,
inhibition of promastigotes growth was
microscopically determined by counting parasite
numbers in a haemocytometer. Inhibition of para-
site growth was determined by comparison to un-
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treated controls. The phototoxic effect was dem-
onstrated by comparing the activity of phthalo-
cyanines with and without illumination. Each ex-
periment was repeated by three times.
Analysis
ED50 and ED90 values were calculated by sigmoi-
dal regression analysis (MSx/fitTM; ID Business
Solution, Guildford, UK). Results were expressed
as mean ± SEM and statistical significance was
determined by Student’s t-test.
Results
Photosensitivity of L. chagasi and
L. panamensis to aluminium and
zinc phthalocyanines
L. chagasi promastigotes were 30 to 50 times more
photosensitive than L. panamensis after AlPc treat-
ment with ED50 values of 0.0033, 0.0093 and
0.0083 µM versus 0.17, 0.25, 0.34 µM of AlPc at
light intensities of 10.0 J/cm2, 5.0 J/cm2 and 2.5
J/cm2 respectively (table 1). A  dose response was
observed in the activity of AlPc on the strains of
both parasites species. In contrast, both species
of Leishmania showed the same range of
photoactivity after ZnPc treatment (table 2). No
significant parasite inhibition was induced on non-
phthalocyanine treated parasites after illumination.
This result indicates that the parasite inhibition
was due to the photosensitization effect of the
phthalocyanine compound under visible light.
Level of photoactivity induced by aluminium
and zinc phthalocyanine
In all assays, AlPc treatment induced more
phototocixity than ZnPc. Aluminium phthalocyanine
was 30 to 40 times and 1,500-2,000 times more
photoactive than ZnPc on L. panamensis and L.
chagasi promastigotes respectively (tables 1
and 2).
No inhibition on both parasites species was in-
duced by AlPc or ZnPc treatment on the dark
(tables 1 and 2). At the maximal dose of any of
the Pc used (15 µM), only up to 5% of parasite
inhibition was observed without illumination.
Photoactivity induced by
hexadecylphosphocholine and amphotericin B
No photoactivity was induced by the reference
drugs after illumination at 5.0 J/cm2 and 2.5 J/
cm2 (data not shown). Without illumination, HPC
was active against L. panamensis and L. chagasi
promastigotes with ED50 values of 4.15 µM (P95
confidence limits 3.85-4.45 µM) and 1.80 µM (P95
confidence limits 1.56-2.04 µM) respectively after
3 days of incubation. In addition, AmB was active
Table 1. Photoactivity of aluminium phthalocyanine chloride against Leishmania spp. promastigotes.
Experiment 1 Experiment 2
J/cm2 ED50 ED90 ED50 ED90
(CL) (CL) (CL) (CL)
L. panamensis 10.0 0.17 6.61 0.15 3.11
(0.12-0.21) (2.85-10.36) (0.14-0.16) (2.11-4.11)
5.0 0.25 15.64 0.27 6.15
(0.22-0.28) (0.72-32.00) (0.17-0.36) (2.47-9.82)
2.5 0.34 8.63 0.26 7.69
(0.27-0.41) (0.97-16.26) (0.23-0.29) (4.10-11.28)
0.0 >15.00 >15.00 >15.00 >15.00
L. chagasi 10.0 0.0033 0.1037 0.0020 0.0733
(0.0024-0.0043) (0.0377-0.1697) (0.0020-0.0020) (0.0362-0.1105)
5.0 0.0093 0.1373 0.0087 0.1686
(0.0069-0.0118) (0.1045-0.1702) (0.0031-0.0143) (0.1291-0.2082)
2.5 0.0083 0.1503 0.0077 0.0997
(0.0074-0.0093) (0.1250-0.1757) (0.0058-0.0095) (0.0727-0.1266)
0.0 >15.00 >15.00 >15.00 >15.00
ED50 and ED90 values in µM with P95 confidence limits (CL); light intensity in J/cm2.
53
Biomédica 2006;26(Supl.1):49-56 PHOTODYNAMIC ACTIVITY OF PHTHALOCYANINES IN LEISHMANIA
Table 2. Photoactivity of zinc phthalocyanine against Leishmania spp. promastigotes.
Experiment 1 Experiment 2
ED50 ED90 ED50 ED90
J/cm2 (CL) (CL) (CL) (CL)
L. panamensis 10.0 6.05 >15.00 4.89 >15.00
(5.00-7.11) (4.65-5.13)
5.0 7.78 >15.00 6.71 >15.00
(7.53-8.03) (5.48-7.93)
2.5 12.38 >15.00 10.22 >15.00
(958-15.18) (9.39-11.06)
0.0 >15.00 >15.00 >15.00 >15.00
L. chagasi 10.0 6.45 >15.00 3.31 >15.00
(5.77-7.13) (2.07-4.55)
5.0 11.58 >15.00 6.68 >15.00
(10.77-12.39) (5.46-7.87)
2.5 >15.00 >15.00 12.36 >15.00
(12.00-12.71)
0.0 >15.00 >15.00 >15.00 >15.00
ED50 and ED90 values in µM with P95 confidence limits (CL); light intensity in J/cm2.
against L. panamensis and L. chagasi with ED50
values of 0.11 µg/mL (P95 confidence limits 0.10-
0.12 µg/mL) and 0.025 µg/mL (P95 confidence limits
0.021-0.028 µg/mL) respectively.
Discussion
The phototoxic effect of phthalocyanines against
strains of two Leishmania species was determined
for the first time in this work. The antileishmanial
activity induced by the photodynamic treatment
in vitro was strongly dependent on both the Leish-
mania species and the type and concentration of
phthalocyanine used.
Leishmania chagasi promastigotes were highly
susceptible to photodynamic therapy in vitro using
AlPc treatment and red light illumination at 670
nm. The range of activities induced by AlPc (between
ED50 of 0.0033 to 0.0093 µM) was lower than other
antileishmanial drug activities such as hexa-
decylphosphocholine and amphotericin B  (25-27).
The efficacy of photodynamic therapy on
trypanosomatids has been demonstrated in previ-
ous studies. The ability to inactivate Trypanosoma
cruzi parasites from blood components was ob-
served using photosensitizers such as
amotosalen or psoralen and ultraviolet illumination
(11,28) and cationic silicon phthalocyanines and
red light illumination (28). In addition, a high
photosensitivity was showed by transgenic
Leishmania promastigotes after ultraviolet
il lumination previously treatment with
aminolevulinic acid (20).
There are two types of mechanism that could be
involved in the parasites inhibition after photody-
namic therapy. The type I mechanisms due to the
production of hydroxyl radicals and other active
oxygen species that react with biomolecules in
situ with subsequent cytotoxic results. The type II
mechanism induced by the reactions between sin-
glet oxygen with molecules involved in the main-
tenance of cell-wall/membrane structures such as
phospholipids, peptides and sterols. Because it
is known that Leishmania promastigotes are very
susceptible to active oxygen species (29-31), it is
possible to suggest that the low concentration of
AlPc used in this study induces the release of
activated oxygen species to inhibit the parasite.
The mechanisms involved in Leishmania
photodamage are under study.
The difference in drug sensitivity between the two
strains pertaining to two species of Leishmania
such as L. chagasi and L. panamensis was
notable. Over fifteen species of Leishmania are
known to cause disease in humans with a wide
clinical spectrum from visceral to cutaneous
manifestations. Each species of Leishmania has
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specific biochemical and molecular characteristics
that provide the basis for the taxonomy of this
genus. These differences are reflected in the
variable sensitivity of Leishmania species to
drugs, for example, pentavalent antimonials (32),
the aminoglycoside antibiotic paromomycin
(aminosidine) (33), several azoles (34), the
pyrazolopyrimidines allopurinol and allopurinol
riboside (35) and hexadecylphosphocholine (27).
But why the strain of L. chagasi used was almost
50 times more sensitive than L. panamensis to
photodynamic therapy it is not known. Almost all
the literature about the in vitro photodynamic
therapy activities is coming from the cancer
models. In these models, the cell toxicity induced
by phthalocyanines in vitro has been shown to be
dependent on factors such as type of tumour cell,
metal phthalocyanine and its derivatives, cell
uptake, phthalocyanine incubation time, light
intensity and/or phthalocyanine localization and
distribution in the cells (16,36-40).
In this work two types of phthalocyanines were
compared. Aluminium phthalocyanine treatment
showed a higher phototoxic effect than ZnPc. This
result could be attributed to the amphiphilic
properties of AlPc that could facilitate cell uptake
and intracellular localization, contrary to the
hydrophobicity of ZnPc. The AlPc used in this
study was soluble in culture medium, whereas
ZnPc was less soluble. In general, phthalocyanines
are prone to self-aggregation and dimers are
reported to be inactive or much more inefficient
than monomers as photosensitizers (17). In water,
ZnPc displays a strong tendency to form
aggregates as a result of the propensity of the
large hydrophobic skeleton to avoid contact with
the aqueous medium. On the other hand, it is
known that the central metal ligand plays a crucial
role in the photobiological activity influencing the
excited triplet state yield and lifetime (16,17).
Another important reason which could justify the
difference in AlPc versus ZnPc activity against
parasites was the type of illumination system used
in this study. It could be possible to obtain a higher
ZnPc activity using a wide range of wavelength
for illumination.
In this paper, we have demonstrated that AlPc
and ZnPc treatment after red light illumination at
670 nm effectively inhibits L. chagasi and L.
panamensis promastigotes. In order to confirm the
useful of photodynamic therapy in leishmaniasis,
it is imperative to continue this study testing the
phothoactivity of these compounds in axenic or
intracellular amastigotes and further in animal
models. However the results shown in this paper,
using only the promastigote free form of the para-
site, give us an idea about the effects of photody-
namic therapy on Leishmania and open a new
perspective for an alternative treatment against
this insidious parasite.
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